Quetiapine for postpartum depression: safety and tolerability
About this title
Read the official source — NCT04950868This study evaluates the safety and effectiveness of Quetiapine for people with depression.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Quetiapine for people with depression.
Who could participate?
Listed age limits: 18 years to 45 years.
What will I do during this study?
The study group receives quetiapine as a study medication.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 22
- Sponsor
- Verinder Sharma
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Canada
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT04950868
- Official title
Show the full official title
A Pilot Study on the Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression
Recruitment & locations
London
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Quetiapine for people with depression.
Who is behind this study?
The study sponsor is Verinder Sharma.
Does this study involve medication?
Yes. The study involves medication, including Quetiapine.
Who can participate?
Listed age limits: 18 years to 45 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
